Table 2.

Acrylamide and glycidamide adduct values in individuals with PC concentrations <10 and ≥10 ng/mL

Acrylamide adducts (pmol/g Hb)
Glycidamide adducts (pmol/g Hb)
Glycidamide to acrylamide adduct ratio
PC < 10 ng/mL*
PC ≥ 10 ng/mL*
PC < 10 ng/mL
PC ≥ 10 ng/mL
PC < 10 ng/mL
PC ≥ 10 ng/mL
N

73
88
73
88
73
88
Median (95% CI)51 (46-56)194 (164-215)34 (31-36)107 (86-123)0.67 (0.63-0.74)0.55 (0.51-0.59)
PercentilesMin7604170.110.03
5298716410.420.32
254012828710.560.46
5051194341070.670.55
7563255411430.810.65
951554031172151.030.92
Max6105843193641.131.14
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
N
25
48
69
19
25
48
69
19
25
48
69
19
Median (95% CI)
49 (40-66)
52 (46-57)
194 (155-215)
182 (129-235)
33 (28-40)
34 (31-37)
100 (82-121)
138 (70-150)
0.56 (0.53-0.79)
0.72 (0.62-0.79)
0.53§ (0.49 -0.59)
0.61§ (55-74)
PercentilesMin20760724717440.110.380.030.46
523328891112136510.290.460.290.47
253941125139272971740.520.620.420.55
50495219418233341001380.560.720.530.61
75706126323142401341490.760.860.640.73
95299974563251621072141950.821.060.920.89
Max6101785483993191583642600.891.131.140.94
  • * Smoking status was assigned based on categories described by Benowitz (28) with presumed smokers having plasma cotinine values of ≥10 ng/mL and presumed nonsmokers <10 ng/mL.

  • Significant differences (P < 0.0001).

  • Significant differences (P < 0.005).

  • § Significant differences (P < 0.05).